eISSN 2508-3589
pISSN 2508-1926

Fig. 2.

Download original image
Fig. 2.

Mean change in central macular edema (CMT) from baseline during the follow-up period. CMT decreased significantly at 1, 2, 3, 4, and 6 months in the bevacizumab group, and at 1, 2, 3, 5, and 6 months in the dexamethasone group. Mean CMT was thinner in the DEX group at 1, 5, and 6 months.

J Retin 2019;4:84-92 https://doi.org/10.21561/jor.2019.4.2.84
© 2019 J Retin